STOCK TITAN
  1. Home
  2. News
  3. COLL

Collegium Pharmaceutical, Inc. - COLL STOCK NEWS

Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a pioneering specialty pharmaceutical company dedicated to developing and commercializing next-generation, abuse-deterrent products aimed at treating chronic pain and other serious medical conditions. Leveraging its proprietary DETERx® technology platform, Collegium creates formulations designed to mitigate the risks associated with the misuse and abuse of prescription medications. The DETERx technology maintains the extended-release and safety profiles of commonly abused drugs, such as opioids and amphetamines, even when subjected to tampering methods like crushing, chewing, or dissolving.

Collegium's lead product, Xtampza ER™, is an extended-release, oral formulation of oxycodone that incorporates abuse-deterrent properties. The company's product portfolio also includes the Nucynta® Products (extended-release and immediate-release formulations of tapentadol), Belbuca® (buccal film for severe chronic pain), and Symproic® (for opioid-induced constipation).

In recent news, Collegium announced its financial results for the quarter ended September 30, 2023, reporting a solid financial performance and an optimistic outlook for 2025 and 2026. The company achieved record quarterly revenue for Belbuca and has initiated an Accelerated Share Repurchase (ASR) program, further demonstrating its commitment to returning value to shareholders. The extension of Nucynta's regulatory exclusivity through July 2026 has also strengthened the company's future market positioning.

Headquartered in Stoughton, Massachusetts, Collegium continues to focus on operational excellence and disciplined capital deployment to enhance shareholder value. The company remains committed to improving patient outcomes while addressing the growing challenges of prescription drug abuse.

For more details and the latest updates, visit Collegium Pharmaceutical's website.

News

Collegium Provides 2024 Financial Guidance

Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) expects product revenues of $580.0 million to $595.0 million, adjusted operating expenses of $120.0 million to $125.0 million, and adjusted EBITDA of $380.0 million to $395.0 million in 2024. The company also authorized a $150.0 million share repurchase program. Collegium's 2023 financial performance was strong, with over 20% revenue growth and over 35% adjusted EBITDA growth compared to 2022. The company returned $75.0 million in capital to shareholders in 2023 and renegotiated major contracts for its products, positioning it for growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.42%
Tags
none
-
News

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the U.S. Court of Appeals for the Federal Circuit upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision confirms both that the PTAB had statutory authority to issue its final decision, and that the PTAB did correctly conclude that the ʼ961 patent was invalid.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News

Collegium Announces $25 Million Accelerated Share Repurchase Program

Rhea-AI Summary
COLL: Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Agreement with Jefferies LLC, part of $100 million share repurchase program. President and CEO Joe Ciaffoni highlights record financial performance and commitment to returning value to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
buyback
News

Collegium to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) to participate in investor conferences. Fireside chats at Jefferies 14th Annual Global Healthcare Conference on Nov 14 and Piper Sandler 35th Annual Healthcare Conference on Nov 28. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
conferences
-
News

Collegium Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
COLL: Collegium Pharmaceutical Reports Q3'23 Net Revenue of $136.7 Million, Up 8% YoY, Records Adjusted EBITDA of $89.4 Million, and Extends Nucynta Regulatory Exclusivity through July 2026
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
earnings
-
News

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Collegium Pharmaceutical will report its Q3 2023 financial results on November 7, 2023, followed by a conference call and webcast. Access details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences earnings
News

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

Rhea-AI Summary
Collegium Pharmaceutical will present 10 posters at PAINWeek Conference 2023, highlighting data on their pain portfolio. The presentations will provide insights for healthcare decision makers. No concrete business takes affecting stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
News

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

Rhea-AI Summary
Collegium Pharmaceutical receives New Patient Population exclusivity for Nucynta, extending U.S. exclusivity period from June 2025 to July 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
News

Collegium Announces $50 Million Accelerated Share Repurchase Program

Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announces an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock, reinforcing confidence in Collegium's core business and financial strength. The ASR is part of a $100 million share repurchase program authorized by its Board of Directors in January 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
buyback
News

Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

Rhea-AI Summary
Collegium Pharmaceutical reports Q2'23 net revenue of $135.5M, up 10% YoY. Q2'23 GAAP net income of $13.0M. Q2'23 adjusted EBITDA of $85.8M, up 21% YoY. Board authorizes $50M share repurchase program. Reaffirms full-year 2023 guidance. Conference call scheduled for today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.68%
Tags
none

FAQ

What is the current stock price of Collegium Pharmaceutical (COLL)?

The current stock price of Collegium Pharmaceutical (COLL) is $29.51 as of January 3, 2025.

What is the market cap of Collegium Pharmaceutical (COLL)?

The market cap of Collegium Pharmaceutical (COLL) is approximately 931.7M.

What is Collegium Pharmaceutical, Inc.?

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing abuse-deterrent products for chronic pain and other serious medical conditions.

What is DETERx® technology?

DETERx® is Collegium's proprietary technology platform designed to maintain the extended-release and safety profiles of commonly abused drugs even when tampered with.

What are the main products offered by Collegium?

Collegium's product portfolio includes Xtampza ER™, Nucynta® Products, Belbuca®, and Symproic®.

What recent financial achievements has Collegium reported?

Recently, Collegium reported strong financial results for Q3 2023, achieving record revenue for Belbuca and initiating an Accelerated Share Repurchase program.

Where is Collegium Pharmaceutical headquartered?

Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts.

How does Collegium's DETERx® technology help in preventing drug abuse?

DETERx® technology ensures that the extended-release and safety profiles of drugs are maintained even if the drugs are tampered with, thus deterring abuse.

What is Xtampza ER™?

Xtampza ER™ is an abuse-deterrent, extended-release, oral formulation of oxycodone developed by Collegium.

How does Collegium Pharmaceutical return value to its shareholders?

Collegium engages in disciplined capital deployment, including share repurchase programs, to return value to shareholders.

What is the significance of Nucynta's regulatory exclusivity extension?

The extension of Nucynta's regulatory exclusivity through July 2026 bolsters Collegium's market position and future revenue streams.

How can I stay updated on Collegium Pharmaceutical's latest news?

You can visit Collegium Pharmaceutical's official website or follow their press releases and financial reports for the latest updates.
Stock COLL logo
Collegium Pharmaceutical, Inc.

Nasdaq:COLL

COLL Rankings

#2607 Ranked by Market Cap
N/A Ranked by Dividends

COLL Stock Data

931.71M
31.73M
1.64%
122.01%
18.94%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
STOUGHTON